top of page

Tue, Feb 28

|

Madonna Inn

Verdinexor: A Novel Oral Therapy for Canine Lympoma

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1.

Registration is closed
See other events
Verdinexor:  A Novel Oral Therapy for Canine Lympoma
Verdinexor:  A Novel Oral Therapy for Canine Lympoma

Time & Location

Feb 28, 2023, 6:00 PM

Madonna Inn, Madonna Inn, San Luis Obispo, CA 93401, USA

About the Event

Speaker: Julie Kluxdal, DVM

Topic: "Verdinexor: A Novel Oral Therapy for Canine Lymphoma"

This lecture will discuss the novel class of drugs called SINE inhibitors, with emphasis on verdinexor (Laverdia-CA1). We will review SINE mechanism of action, along with a thorough review of the data leading to a reasonable expectation of efficacy and FDA conditional approval of Laverdia-CA1. We will also look at where this new oral option fits into specialty and primary care practice therapies as consideration for future use. The attendee will learn how to properly dose and safely dispense verdinexor as well as how to monitor the lymphoma patient on verdinexor, including how to address any potential adverse events.

Dinner Meeting

Madonna Inn Restaurant

100 Madonna Rd

San Luis Obispo, CA 93405

805-543-3000

Tuesday, February 28, 2023

Check-In: 6:00 PM - 6:30 PM, Pacific

Presentation: 6:30 PM - 7:30 PM, Pacific

Register by: Tuesday, February 21, 2023 by using the following link:

https://www.eventbrite.com/e/canine-lymphoma-23085-tickets-525723622507

CE Credits: 1

Contact:

Jamie Havard, Territory Manager

559-789-6820

Jamie.Havard@dechra.com

This is a private event for members of the MCVMA.

Share This Event

bottom of page